Denileukin diftitox (trade name Ontak) is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 ...
This page contains brief information about denileukin diftitox and a collection of links to more information about the use of this drug, research results, and ongoing ...
(de-ni-LOO-kin dif-ti-tox) Trade names: Ontak ® Chemocare.com uses generic drug names in all descriptions of drugs. Ontak is the trade name for denileukin diftitox.
Denileukin diftitox. On October 15, 2008, the U. S. Food and Drug Administration converted the approval of denileukin diftitox (Ontak®, Eisai Medical Research ...
Learn about the prescription medication Ontak (Denileukin Diftitox), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling.
What is denileukin diftitox? Denileukin diftitox is a designed protein containing toxins that attach themselves to certain types of malignant cells in the body.
Denileukin diftitox has been very effective in treating cutaneous lymphoma; it causes rapid tumor lysis by inhibiting protein synthesis in cells that express the ...
Summary. The FDA-approved drug label for denileukin diftitox (Ontak) notes that it is indicated for patients with persistent or recurrent cutaneous T-cell lymphoma ...
Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Drug Link in Drugs@FDA Therapeutic Area HUGO Symbol Referenced Subgroup Labeling Sections with Pharmacogenomic Information; Denileukin Diftitox: Oncology